Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC

Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC

This study evaluated the efficacy and safety of camrelizumab combined with platinum-based chemotherapy (taxanes [T] or fluorouracil agents [F] plus platinum [P] drugs) as the first-line treatment in advanced esophageal squamous cell carcinoma (ESCC), using immune repertoire sequencing (IRS) to explo...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoling Zhang, Wenqi Zhao, Yunyi Du, Fei Su, Yuexiang Zhang, Hui Wang, Yongai Li, Min Liu, Yangjun Gao, Linlin Cai, Tingting Feng, Mei Wang, Chunmei Yao, Ning Xu, Yu Wang, Guohua Song, Wenqing Hu, Jun Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
camrelizumab
esophageal squamous cell carcinoma
immune repertoire sequencing
T-cell receptor beta-chain
immunoglobulin heavy chain
treatment response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1526443/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1526443/full

Similar Items